RxDoctor Payments Data

Dixitkumar Modi, MD

Family Medicine · Cocoa Beach, FLNPI 1124238506

Payments from drug & device makers

$1,682in general payments, 2019–2025

Across 82 payments — averaging $20.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$265
  • Lilly USA, LLC$226
  • Phathom Pharmaceuticals, Inc.$207
  • AbbVie$129
  • AstraZeneca$125
  • Idorsia Pharmaceuticals US Inc$110
  • plus $619 from 13 others

What the payments were for

  • Food & beverage$1,682100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,682 in reported general payments places this provider in the 70th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$327,326
Medicare patients
786
Services billed
5,121

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban189$210,312
JardianceEmpagliflozin142$186,538
OzempicSemaglutide149$149,354
TrulicityDulaglutide55$83,066
MounjaroTirzepatide56$71,067
JanuviaSitagliptin Phosphate41$46,632
XareltoRivaroxaban49$42,001
EntrestoSacubitril/Valsartan23$33,856
Trelegy ElliptaFluticasone/Umeclidin/Vilanter43$32,600
Tresiba Flextouch U-100Insulin Degludec33$31,754
FarxigaDapagliflozin Propanediol24$24,645
Fluticasone-SalmeterolFluticasone Propion/Salmeterol82$24,159
MyrbetriqMirabegron19$20,332
Spiriva HandihalerTiotropium Bromide16$19,201
Repatha SureclickEvolocumab20$17,617

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Abrysvo$72$224,265236 claims
Boehringer IngelheimJardiance$31$186,538142 claims
Novo NordiskOzempic, Wegovy$85$166,129162 claims
Lilly USA, LLCTrulicity, Mounjaro$226$154,133111 claims
MerckJanuvia, Lagevrio (Eua)$53$55,14554 claims
Johnson & JohnsonXarelto$77$42,00149 claims
AstraZenecaFarxiga, Symbicort$125$36,75653 claims
Astellas Pharma US IncMyrbetriq$15$20,33219 claims
AbbVieLinzess, Synthroid$129$19,238115 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Cocoa Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →